iiinova — where your digital self keeps evolving

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · 22/09/2026

We dont see fewer advanced stage cancers by ordering these tests But people will still order them to those willing to pay, because ... anecdotes (and to be clear, I dont support that)

000

Reposted by Syed Mohi Ahmed, MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 10/09/2026

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented MO15.02 A Phase 2 Trial of QLC5508 (MHB088C) Plus QL1706 or QL2107 as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

012

Reposted by Syed Mohi Ahmed, MD, PhD

Lung Cancer Europe @lungcancereurope.bsky.social · 13/09/2026

🧠 Phase 3 MAVERICK results at #WCLC26 could change care for small cell #lungcancer. MRI surveillance alone protected cognitive outcomes vs adding preventive brain radiotherapy, with no significant diff in survival so far. If confirmed, this could spare some people with #SCLC unnecessary treatment.

051

Reposted by Syed Mohi Ahmed, MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 01/09/2026

Our OncoAlert TOP 10 for #WCLC26 with a focus on Advanced Non-Small Cell #LungCancer #NSCLC Lead Dr. Hidehito Horinouchi 🇯🇵 Dr. Uğur Özkerim🇹🇷 Dr. Oriol Mirallas🇺🇸 Dr. Gil Morgan 🇺🇸 Faculty Dr. Charu Agarwal🇺🇸 Dr. Stephen Liu🇺🇸 Dr. Gilberto Lopes🇺🇸 Dr. Sanjay Popat🇬🇧 Dr. Solange Peters 🇨🇭

001

Reposted by Syed Mohi Ahmed, MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 04/09/2026

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week Safety and Efficacy of QLC1101 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS G12D Mutation ✅ Well tolerated — grade ≥3 TRAEs 9.6%, none causing discontinuation or death.

001

Reposted by Syed Mohi Ahmed, MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 04/09/2026

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.01 — Efficacy and Safety of GFH375 in Advanced KRASG12D Mutant Non-Small Cell Lung Cancer (NSCLC) Patients ✅ Compelling single-arm activity with tolerable safety in a heavily pretreated population.

001

Reposted by Syed Mohi Ahmed, MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 04/09/2026

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.04 — A Single-Arm Phase 2 Study of First-Line Amivantamab, Lazertinib, Pemetrexed in EGFR-mutant NSCLC: AMIGO-1 (LACOG 0821)

012

Reposted by Syed Mohi Ahmed, MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 04/09/2026

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA14.05 — Ivonescimab-Chemo vs Placebo-Chemo in EGFR-TKI-Resistant, EGFR-Mutated NSCLC (HARMONi): Updated Overall Survival Analysis ✅ OS benefit durable and consistent across regions, no new safety signals

022

Reposted by Syed Mohi Ahmed, MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 09/09/2026

FDA News🇺🇸 Sevabertinib Approved in Locally Advanced #NSCLC #LungCancer On September 9, 2026, the FDA granted accelerated approval to sevabertinib (Hyrnuo) for adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 (ERBB2) TKD activating mutations www.fda.gov/drugs/resour...

001

Reposted by Syed Mohi Ahmed, MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 10/09/2026

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstracts to be presented Next week OA05.02 Phase 1 Study of LB2102, a dnTGFBR2-armored DLL3-targeted Autologous CAR-T Cell Therapy, in Subjects With Relapsed or Refractory #SCLC or LCNEC

001

Reposted by Syed Mohi Ahmed, MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 10/09/2026

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented MO15.04 First-Line YL201 Plus Serplulimab in ES-SCLC and Advanced NSCLC: Phase 1 Results of a B7-H3-Directed Combination Strategy

001

Reposted by Syed Mohi Ahmed, MD, PhD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 11/09/2026

The 🚨 OncoAlert TOP 10 — #WCLC26 🌐 👉Advanced #SCLC & #Mesothelioma 🇰🇷 We’re kicking off our OncoAlert TOP 10 for #WCLC26 with a focus on Advanced Small Cell #LungCancer ( #SCLC ) and Mesothelioma🫁

001

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · 13/09/2026

Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher. Full phase 3 TAISHAN-302 trial results: nej.md/4xKtvcF #WCLC26

This image consists of Kaplan–Meier curves for overall survival in the intention-to-treat population.

072

Reposted by Syed Mohi Ahmed, MD, PhD

American Society of Clinical Oncology @ascocancer.bsky.social · 31/05/2026

Major news from #ASCO26: A multi-selective RAS(ON) inhibitor nearly doubles survival time in people with metastatic pancreatic cancer. “This is absolutely practice-changing” says Dr. Shruti Patel in this Science in Seconds. #pancan Read the abstract: bit.ly/4dChEWM

163

Reposted by Syed Mohi Ahmed, MD, PhD

American Society of Clinical Oncology @ascocancer.bsky.social · 31/05/2026

The latest from #ASCO26 Plenary: Ivonescimab + chemo yields superior OS vs tislelizumab + chemo in previously untreated advanced squamous NSCLC, per new results from the phase 3 HARMONi-6 trial conducted in China: bit.ly/49qr1WW #ASCODailyNews

022

Reposted by Syed Mohi Ahmed, MD, PhD

Robert S Miller MD @rsm2800.bsky.social · 31/05/2026

Dr. Wolpin gets a well-deserved standing ovation at the plenary session of #ASCO26 for this K-M curve

151

Reposted by Syed Mohi Ahmed, MD, PhD

Medthority @medthority.bsky.social · 01/06/2026

Dr Fred Saad reports on PSMAddition subgroup analysis: 177Lu PSMA 617 + ADT + ARPI improves rPFS across mHSPC 📈 • Consistent benefit across disease volume and de novo/recurrent subgroups ✅ • Safety and PROs similar across groups #ProstateCancer #ASCO26 #Oncology #MedEd

001

Reposted by Syed Mohi Ahmed, MD, PhD

Medthority @medthority.bsky.social · 01/06/2026

Dr Kim N Chi shares PLUDO crossover analysis: 177Lu-PSMA-617 vs docetaxel in mCRPC 🔁 • No significant differences in rPFS or OS between sequences • Supports use of both therapies in patients progressing after ARPI #ProstateCancer #ASCO26 #Oncology #MedEd

001

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · 31/05/2026

At a median follow-up of 11.8 months (range, 1.1-21.9), median PFS and OS were 6.8 months (95% CI, 5.2-8.3) and 12.5 months (95% CI, 10.2-16.8), respectively... greater antitumor activity in participants [with previous] ICI and chemotherapy than what has been reported for paclitaxel or cetuximab.

020

Reposted by Syed Mohi Ahmed, MD, PhD

American Society of Clinical Oncology @ascocancer.bsky.social · 31/05/2026

In this exclusive set of First Look videos from #ASCODailyNews, Dr. Monty Pal of @cityofhope.bsky.social discusses each of the 5 Plenary abstracts before they're presented later today at #ASCO26: bit.ly/4dOUfA6

001

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · 31/05/2026

Apalutamide group VS placebo group with no evidence of disease at 4 years (21.9% vs. 18.3%; odds ratio, 1.25; P=0.04) After a median follow-up of 5 years, with an overall mortality of 8.5%, overall survival in the apalutamide group as compared with the placebo group, HR for death of 1.08

110

Reposted by Syed Mohi Ahmed, MD, PhD

Deb Maskens @debmaskens.bsky.social · 31/05/2026

Looking forward to expert discussion on RAMPART. Interesting that monotherapy arm was negative. Side effects significant in double immunotherapy, but no meaningful difference in Qol? Note: 3 grade 5 events (deaths)in Adjuvant setting. #kidneycancer #kcsm #ASCO26

001

Reposted by Syed Mohi Ahmed, MD, PhD

The Canadian Cancer Trials Group @cctg.bsky.social · 31/05/2026

A simple blood test may detect tumor relapse in patients with early-stage germ cell tumors. The interim results of the @swog.org S1823 (#CCTG GCC1) study presented at #ASCO26 could identify patients at higher risk of relapse earlier Presented by #DrLuciaNappi buff.ly/wLDl01S @vchresearch.bsky.social

022

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · 31/05/2026

Among patients with 𝘙𝘌𝘛 fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels. Full phase 3 LIBRETTO-432 trial results: nej.md/3Q3QcIo #ASCO26

0133

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · 31/05/2026

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM #ASCO26

15030

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · 31/05/2026

I can attest to this reality And a lot of it comes from ... increasing documentation requirements "Scribe is help you document, so now you can document more"

000

Reposted by Syed Mohi Ahmed, MD, PhD

Dana-Farber Cancer Institute @danafarber.bsky.social · 30/05/2026

New research from @atishchoudhury.bsky.social, MD, PhD, looks at whether treatment can be safely scaled back for certain patients with metastatic prostate cancer who responded exceptionally well to androgen receptor pathway inhibitor therapy. #ASCO26

021

Reposted by Syed Mohi Ahmed, MD, PhD

Dana-Farber Cancer Institute @danafarber.bsky.social · 30/05/2026

Alicia Morgans, MD, MPH, reports that in the first randomized U.S. study of cognitive effects in advanced prostate cancer, darolutamide led to less decline in thinking and memory than enzalutamide over 24 weeks (n=111). #ASCO26

141

Reposted by Syed Mohi Ahmed, MD, PhD

Tian Zhang, MD @tiansterzhangmd.bsky.social · 30/05/2026

@AtishChoudhury @DanaFarber_GU reports #ADREAM, a trial of de-intensification for metastatic AR sensitive #prostatecancer. Median 2 years off tx — holding tx is feasible and could be an approach in excellent responders. Sets up #LIBERTAS trial & others. #ASCO26 @oncoalert @asco

011

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · 31/05/2026

meetings.asco.org/meetings/202... Plenary presentations upcoming tomorrow

000

Reposted by Syed Mohi Ahmed, MD, PhD

OncLive @onclive.bsky.social · 30/05/2026

🎯 Bezuclastinib + sunitinib cut the risk of disease progression or death by 50% vs sunitinib alone in advanced GIST after imatinib, with a median PFS of 16.5 vs 9.2 months and an ORR of 46% vs 26%. 📊🧬 Read more ➡️ www.onclive.com/view/bezucla... #GIST #ASCO26 #Oncology @ascocancer.bsky.social

onclive.com

Bezuclastinib Plus Sunitinib Cuts Risk of Progression or Death in Half vs Sunitinib Alone in Advanced GIST | OncLive

Bezuclastinib plus sunitinib decreased the risk of progression or death by 50% compared with sunitinib monotherapy in GIST.

011

Reposted by Syed Mohi Ahmed, MD, PhD

Yale Cancer Center @yalecancer.bsky.social · 31/05/2026

Dr. Barbara Burtness shared updated results from KEYNOTE‑412 in unresected locally advanced #HNSCC. In pts with high PD‑L1 expression, adding pembro to CRT improved outcomes vs CRT alone. #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social

011

Reposted by Syed Mohi Ahmed, MD, PhD

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 28/05/2026

After lorlatinib, what comes next for ALK+ #lungcancer? New ASCO 2026 data on neladalkib - the Nuvalent trial - shows 31% response in heavily pre-treated patients, rising to 46% without prior lorlatinib. Early data, not yet approved. But a real signal. Abstract 8503 #ASCO26 #LCSM

182

Reposted by Syed Mohi Ahmed, MD, PhD

Conquer Cancer, the ASCO Foundation @conquercancer.bsky.social · 28/05/2026

This week, Dr. Brian Wolpin, a 2009 Conquer Cancer grant recipient, will deliver keynote updates on the #ASCO26 plenary stage to present findings on daraxonrasib, a targeted KRAS inhibitor that nearly doubled the median survival in advanced pancreatic cancer. Read more: bit.ly/49WSeRg

001

Reposted by Syed Mohi Ahmed, MD, PhD

OncLive @onclive.bsky.social · 26/05/2026

Rahul Banerjee, MD, FACP, previews the phase 3 SUCCESSOR-2 trial evaluating mezigdomide in combination with carfilzomib and dexamethasone, which will be presented at #ASCO26 #mmsm Read more on the most anticipated @ascocancer.bsky.social myeloma abstracts here www.onclive.com/view/frontli...

001

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · 29/05/2026

Phase 3 MajesTEC-9 trial: In relapsed multiple myeloma, teclistamab improved 18-month progression-free survival as compared with standard therapy. Grade 3 or 4 infections were common; antimicrobial prophylaxis and immune globulin support were recommended. nej.md/3PvpJDr #ASCO26

194

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · 30/05/2026

Phase 3 TALAPRO-3 trial: In patients with metastatic prostate cancer with gene alterations, talazoparib–enzalutamide led to better progression-free survival outcomes than placebo–enzalutamide but with more serious adverse events. nej.md/4nRSB5n #ASCO26 | @ascocancer.bsky.social

Line graph showing investigator-assessed imaging-based progression-free survival in the intention-to-treat population. Two lines represent different treatment groups: blue for talazoparib plus enzalutamide, and gray for placebo plus enzalutamide. A table below displays the number of patients at risk for both groups at various time intervals.

041

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · 30/05/2026

Ugandan children with sickle cell anemia who received 10 years of hydroxyurea therapy had sustained laboratory and clinical benefits, improved growth, and few toxic effects. Read the full summary of research findings: nej.md/4nRSBlT

This image displays four graphs comparing growth patterns between children labeled "Girls" and "Boys." Graph A shows height by age. Graph B presents weight by age. Graph C illustrates body-mass index by age. Graph D depicts the cumulative incidence of Tanner Stage 2 development. Two lines are shown: one for "Breasts and Genitals" and one for "Pubic Hair," each indicating progression for both groups.

0215

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · 30/05/2026

In HER2-positive gastroesophageal adenocarcinoma, progression-free survival was longer with zanidatamab plus chemotherapy, both with and without tislelizumab, than with trastuzumab plus chemotherapy. Full HERIZON-GEA-01 trial results are summarized in a new Quick Take. nej.md/4dPdxFs

A silhouette of a person with a highlighted stomach. A magnified view shows human epidermal growth factor receptor 2. To the side, medical supplies including two vials and an IV bag are displayed, representing zanidatamab plus tislelizumab plus chemotherapy.

043

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · 29/05/2026

In NSCLC with 𝘌𝘎𝘍𝘙 exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia. Full phase 3 WU-KONG28 trial results: nej.md/4fQWMwa #ASCO26

1103

Reposted by Syed Mohi Ahmed, MD, PhD

American Society of Clinical Oncology @ascocancer.bsky.social · 31/05/2026

Just presented at #ASCO26: TALAPRO-3 results show that combining talazoparib with enzalutamide improves outcomes over enzalutamide alone for men with HRR-altered mCSPC. #ASCODailyNews has more: bit.ly/430i3Mw

011

Reposted by Syed Mohi Ahmed, MD, PhD

Ian Davis @profiand.bsky.social · 13/04/2026

Here are the #ASCO26 sessions at a glance, 2-page view. Friday and Tuesday put together at the end, as they are shorter days and I can only include 4 images. Full document here: cdn.bfldr.com/KOIHB2Q3/as/...

#ASCO26 Program At A Glance for Saturday 30May2026

#ASCO26 Program At A Glance for Sunday 31May2026

#ASCO26 Program At A Glance for Monday 1Jun2026

#ASCO26 Program At A Glance for Friday 29May2026 and Tuesday 2Jun2026

111

Reposted by Syed Mohi Ahmed, MD, PhD

Ravi Madan @ravimadan.bsky.social · 25/02/2026

🔜 #GU26 @ascocancer.bsky.social PFS benefit less than I would have expected… “The median (95% CI) PFS was 14.7 (11.7–21.3) mos among pts in the concomitant ARPI cohort vs 12.5 (11.5–13.6) months in the no concomitant therapy. Ongoing follow-up… on long-term clinical outcomes, including OS.”

021

Reposted by Syed Mohi Ahmed, MD, PhD

MSK Department of Medicine @mskdeptofmed.bsky.social · 28/02/2026

At @ascocancer.bsky.social #GU26, Robert Motzer presented phase 3 trial results that showed belzutifan + lenvatinib achieved superior PFS & ORR compared with cabozantinib in people with advanced #kidneycancer who progressed after immunotherapy. @mskcancercenter.bsky.social 🔗 bit.ly/4r4AYPD

052

Reposted by Syed Mohi Ahmed, MD, PhD

American Society of Clinical Oncology @ascocancer.bsky.social · 28/02/2026

Promising news from #GU26: Research led by @drchoueiri.bsky.social shows that adding #belzutifan to pembrolizumab adjuvant therapy prevented #ccRCC recurrence in high-risk patients better than pembrolizumab alone. Learn more: bit.ly/3OxZdIE

011

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · 02/03/2026

EV + pembro in CisPt eligible pts KEYNOTE-B15/EV-304 study 24-mo estimated EFS rate 79.4% vs 66.2%; HR 0.53 24-mo estimated OS rate 86.9% vs 81.3%; HR 0.65, pCR rate (55.8% vs 32.5%) #GU26

asco.org

Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3...

010

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · 01/01/2026

New in the January 1, 2026, issue of NEJM: Sacituzumab Tirumotecan in EGFR-TKI–Resistant NSCLC (OptiTROP-Lung04 phase 3 trial) nej.md/493hVjl Osimertinib plus Chemotherapy in 𝘌𝘎𝘍𝘙-Mutated NSCLC (FLAURA2 phase 3 trial) nej.md/4opdBzC

Images and descriptions of what's new on NEJM.org this week

172

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · 03/01/2026

At a median follow-up duration of 34.5 months, median PFS was unreached in the teclistamab–daratumumab group versus 18.1 months in the DPd or DVd group, with an estimated 36-month PFS of 83.4% versus 29.7% and an apparent plateauing of the curves beyond this landmark

nature.com

MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma - Nature Reviews Clinical Oncology

Nature Reviews Clinical Oncology - MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma

130

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · 26/12/2025

In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results and Research Summary: nej.md/3WIRtEg

The New England Journal of Medicine
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
A Research Summary based on Powles T et al. | 10.1056/NEJMoa2511885 | Published on October 20, 2025

Visual representations of the patients in the trial and the treatments they were assigned.

Read the full Research Summary at NEJM.org.

083